Top Menu

Bob Ehrlich

DTC in Perspective: Could Amazon Change the Drug Market?

The widely reported story that Amazon is considering entering the prescription drug market has made current drug sellers nervous. Could Amazon revolutionize drug sales? Or, would they just be another mail order supplier in a crowded market? The answer is unclear. Amazon certainly has the strength to cut deals with drug companies, insurers and major […]

Continue Reading 0
Restylane_Refyne_Defyne

A One-on-One with Galderma VP & General Manager of the U.S. A&C Business Unit Alisa Lask: How Digital is Transforming their Patient Communications

In mid-September, DTC Perspectives spoke with Alisa Lask, the VP and General Manager of Aesthetic & Corrective Business Unit from Galderma, about the evolution of their digital marketing. “Digital has had a really powerful impact on the aesthetics brands,” she noted. Galderma’s aesthetics business unit is already seeing a large usage of their various digital […]

Continue Reading 0
Bob Ehrlich

DTC in Perspective: Obamacare Stays, Drug Companies at Risk

With the failure to come up with an alternative to Obamacare, Congress has left drug companies in a more precarious position. The goal was to make health care more free market oriented and less government controlled. That would have created more competition among health care providers and insurance companies. Patients would have more choice and […]

Continue Reading 0
DTC Perspectives | DTC in Focus

Online Health Communities: A New Frontier in Health Research

For years, many luxury goods retailers, concerned about exclusivity and control, either sniffed at or completely ignored the internet as a marketplace. Now, a recent McKinsey & Company Marketing & Sales report tells us “Nearly half of luxury goods buying decisions are already influenced by what consumers hear or see online.” The same report predicts […]

Continue Reading 0